Three compelling British stocks the market has overlooked

Against an uncertain global backdrop, British stocks have touched new highs in 2026, once again showing the UK's resilient nature when compared with other developed markets. As contrarian-minded value investors, we are firm believers in the maxim that “price is what you pay, value is what you get”, and the UK's outperformance has as much to do with the modest starting valuation of many of its companies as with its preponderance of resilient, cash-generative businesses. It's one of the reasons the UK remains a fertile hunting ground for those seeking out under-appreciated stocks that have fallen out of favour with investors but have the scope to deliver strong risk-adjusted returns for those willing to take a longer-term view. The following three companies are examples of businesses we think the market may be overlooking.

Speciality chemicals company Croda (LSE: CRDA) is a British stock with contrarian attractions. The shares are coming out of a period of deep underperformance after a confluence of issues served to undermine the business's former world-class reputation and history of high margins, good growth and attractive returns. End markets have proved tough and high levels of investment in exciting new pharmaceutical-oriented capabilities have yet to pay off. Nevertheless, over time we have become convinced that this business is far from broken and there is scope for substantial improvements in profitability on the back of an ambitious cost-reduction programme, well-invested assets and recovering demand. Shareholders can expect a market-beating yield of more than 4% while they wait.

Communications group WPP (LSE: WPP) is another British stock we think has reached a price that deeply underestimates the intrinsic value of the business. Under new leadership, the business is consolidating so as to leverage the enviable talent and technological prowess at its disposal. After a period of extended underperformance against a tough market backdrop, for the last two consecutive quarters, the company has led the market in winning new business. This supports our view that WPP has turned a corner and reinvigorated its competitiveness in the advertising and marketing business, where scale and data are all-important. There is clear evidence that the business is making real progress in transforming the group's structure, and ample cash on the balance sheet gives the firm options. The shares are trading on an exceptionally undemanding price/earnings ratio of less than five times and offer a yield of well over 6% for the next year, so investors will be well compensated for the risk.

Try 6 free issues of MoneyWeek today

Get unparalleled financial insight, analysis and expert opinion you can profit from.

Start your trial

Sign up to Money Morning

Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter

Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter

Sign up

Chesnara (LSE: CSN) is a lean, tightly run insurer led by a seasoned team that specialises in buying closed life-insurance books, often at big discounts to book value. These acquisitions generate reliable, long-term cash flows, boosted by disciplined cost control and a proven ability to make the most of business synergies. The result is a dividend that rises every year, giving Chesnara the strongest record of continuous growth in UK and European insurance. A transformational deal for HSBC's UK Life business last year lifted the group into the FTSE 250 and delivered a one-off 6% dividend hike. With more deals in sight, a conservative balance sheet and an 8%+ yield, Chesnara stands out as an attractive income play that many won't have considered.

When a business falls out of favour, it sometimes doesn't take much for sentiment to start improving. These British stocks are not without risk, but they could offer rich rewards for patient investors over time.

This article was first published in MoneyWeek's magazine. Enjoy exclusive early access to news, opinion and analysis from our team of financial experts with a MoneyWeek subscription.